prikaz prve stranice dokumenta Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19
  Download
PDF 949.32 KB
master's thesis
Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. urn:nbn:hr:163:462376
Radica, Katarina
University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of biochemistry and molecular biology

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Radica, K. (2023). Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19 (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:462376

Radica, Katarina. "Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. https://urn.nsk.hr/urn:nbn:hr:163:462376

Radica, Katarina. "Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. https://urn.nsk.hr/urn:nbn:hr:163:462376

Radica, K. (2023). 'Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:163:462376

Radica K. Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19 [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2023 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:163:462376

K. Radica, "Verifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:163:462376

Metadata
TitleVerifikacija metoda genotipizacije polimorfizama u genima za CYP2C9 i CYP2C19
Title (english)Verification of Methods for Genotyping Polymorphisms in CYP2C9 and CYP2C19
AuthorKatarina Radica
MentorSandra Šupraha Goreta (mentor)
MentorMario Štefanović (mentor)
Committee memberSandra Šupraha-Goreta (predsjednik povjerenstva)
Committee memberIvana Ćelap (član povjerenstva)
Committee memberMario Štefanović (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of biochemistry and molecular biology)
Zagreb
Defense date and country2023-09-12, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Medical Biochemistry
Abstract
Citokrom P450 enzimi važni su metabolizmu lijekova, posebice CYP1A2, CYP2C9, CYP2C19, CYP2D6 i CYP3A4 koji kataliziraju 90-95 % reakcija u kojima su lijekovi supstrati. S obzirom da su geni za CYP2C9 i CYP2C19 polimorfni, u nekim slučajevima je preporuka odrediti genotip prije početka terapije kako bi se osigurala djelotvornost i smanjio rizik od nuspojava prilagođavajući terapiju ovisno o tipu metabolizatora pacijenta. U Kliničkom zavodu za kemiju Kliničkog bolničkog centra Sestre milosrdnice došlo je do promjene analitičkog sustava za genotipizaciju polimorfizama CYP2C9 i CYP2C19 je u upotrebu uveden Roche Diagnostics LightCycler® 480 II. Cilj ovog rada je bio verificirati analitičke značajke mjernih postupaka genotipizacije polimorfizama CYP2C9 i CYP2C19 prije početka upotrebe analitičkog analizatora u rutinskom radu. Provedeno je ispitivanje analitičke nepreciznosti, analitičke osjetljivosti, analitičke specifičnosti, analitičke točnosti, granica detekcije te usporedivost s drugom metodom. Rezultati vrednovanja mjernog postupka za genotipizaciju polimorfizama gena CYP2C9 i CYP2C19 u potpunosti su zadovoljili unaprijed određene analitičke kriterije kvalitete, stoga se uređaj može uvesti u rutinski rad.
Abstract (english)
Cytochrome P450 enzymes are important in drug metabolism, especially CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 which take part in 90-95 % of reactions in which drugs act as substrates. Since CYP2C9 and CYP2C19 genes are polymorphic, sometimes it is recommended to determine the genotype before starting therapy to ensure efficacy and to reduce the risk of side effects by adjusting therapy depending on the patient's metabolizer type. In University Hospital Center Sestre Milosrdnice, Department of Clinical Chemistry, Roche Diagnostics LightCycler® 480 II has been introduced as a new analytical system for genotyping CYP2C9 and CYP2C19.The aim of this study was to evaluate analytical characteristics of genotyping polymorphism CYP2C9 and CYP2C19. Analytical imprecision, analytical sensitivity, analytical specificity, analytical accuracy, detection limit and repeatability with another method were tested. The results of the evaluation of the measurement procedure for genotyping the polymorphisms of CYP2C9 and CYP2C19 genes have fully met the predetermined analytical quality criteria, therefore the new analytical system can be introduced for routine work.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:462376
Study programmeTitle: Medical biochemistry
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: magistar/magistra medicinske biokemije (magistar/magistra medicinske biokemije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-01-22 13:47:26